Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $52.56
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price […]
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price […]
